Diabetic eye disease;Doença ocular diabética

Acta Medica Portuguesa

Volumn 28, Issue 1, 2015, Pages 107-113

  Henriques, José ^a,b   Vaz Pereira, Sara ^c,d   Nascimento, João ^b,e   Rosa, Paulo Caldeira ^a,b  

^a Instituto de Oftalmologia Dr Gama Pinto   (Portugal)

^b Instituto Retina de Lisboa (IRL)   (Portugal)

^c HOSPITAL DE SANTA MARIA   (Portugal)

^d UNIVERSITY OF LISBON   (Portugal)

^e HOSPITAL BEATRIZ ÂNGELO   (Portugal)

Author keywords

Diabetes complications; Diabetes mellitus; Diabetic retinopathy

Indexed keywords

ARTICLE; BLINDNESS; CATARACT; CORNEA EROSION; CRANIAL NERVE PARALYSIS; DIABETIC RETINOPATHY; GLAUCOMA; HUMAN; ISCHEMIC OPTIC NEUROPATHY; PHYSICIAN; WORK; DIABETES COMPLICATIONS; EYE DISEASES; PATHOPHYSIOLOGY;

DIABETES COMPLICATIONS; DIABETIC RETINOPATHY; EYE DISEASES; HUMANS;

EID: 84923654723     PISSN: 0870399X     EISSN: 16460758     Source Type: Journal    
DOI: 10.20344/amp.5361     Document Type: Article

References (56)

1. UKPDS Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-5.
2. Groeneveld Y, Petri H, Hermans J, Springer MP. Relationship between blood glucose level and mortality in type 2 diabetes mellitus: a systematic review. Diabet Med. 1999;116:2-13.
3. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-12.
4. Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care. 1995;18:258-68.
5. Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little .RR. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care.1998;21:475-6.
6. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21:1414-31.
7. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047-53.
8. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87:4-14.
9. Correia LG, Boavida JM, Almeida JP, Salvador MC, Dores J, Duarte JS, et al. Diabetes: factos e números 2013 − Relatório Anual do www.actamedicaportuguesa.com Observatório Nacional da Diabetes 11/2013. Lisboa: OND; 2013.
10. Cai J, Boulton M. The pathogenesis of diabetic retinopathy: old concepts and new questions. Eye. 2002;16:242-60.
11. Kempen JH, O’Colmain BJ, Leske MC, Haffner SM, Klein R, Moss SE, et al. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol. 2004;122:552-63.
12. Moss SE, Klein R, Klein BE. The 14-year incidence of visual loss in a diabetic population. Ophthalmology. 1998;105:998-1003.
13. Nabais C, Pereira J, Pereira P, Capote R, Morbeck S, Raposo J. Retinopatia diabética e condições associadas, que relação? Um estudo em doentes com diabetes mellitus tipo 2. Acta Med Port. 2011;24:71-8.
14. Jeganathan E, Wang JJ, Wong TY. Ocular associations of diabetes other than diabetic retinopathy. Diabetes Care. 2008;31:1905-12.
15. Cavallerano JD. A review of non-retinal ocular complications of diabetes mellitus. J Am Optom Assoc. 1990;61:533-43.
16. Stanga PE, Boyd SR, Hamilton AM. Ocular manifestations of diabetes mellitus. Curr Opin Ophthalmol. 1999;10:483-9.
17. Ling R, Ramsewak V, Taylor D, Jacob J. Longitudinal study of a cohort of people with diabetes screened by the Exeter Diabetic Retinopathy Screening Programme. Eye. 2002;16:140-5.
18. Williams R, Airey M, Baxter H, Forrester J, Kennedy-Martin T, Girach A. Epidemiology of diabetic retinopathy and macular oedema: a systematic review. Eye. 2004;18:963-83.
19. Klein R. The epidemiology of diabetic retinopathy: findings from the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Int Ophthalmol Clin. 1987;27:230-8.
20. Marinho Falcão I, Pinto C, Santos J, Fernandes MF, Ramalho L, Paixão E, et al. Estudo da prevalência da diabetes e das suas complicações numa coorte de diabéticos portugueses: um estudo na Rede Médicos Sentinela. Rev Port Clin Geral. 2008;24:679-92.
21. Enge M, Bjarnegård M, Gerhardt H, Hardt H, Gustafsson E, Kalén M, et al. Endothelium-specific platelet-derived growth factor-B ablation mimics diabetic retinopathy. EMBO J. 2002;21:4307-16.
22. Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med. 2012;366:1227-39.
23. Kowluru RA, Chan PS. Oxidative stress and diabetic retinopathy. Exp Diabetes Res. 2007;2007:43603.
24. Patel N. Targeting leukostasis for the treatment of early diabetic retinopathy. Cardiovasc Hematol Disord Drug Targets. 2009;9:222-9.
25. El-Asrar AM. Role of inflammation in the pathogenesis of diabetic retinopathy. Middle East Afr J Ophthalmol. 2012;19:70-4.
26. Robison WG, Nagata M, Laver N, Hohman TC, Kinoshita JH. Diabeticlike retinopathy in rats prevented with an aldose reductase inhibitor. Invest Ophthalmol Vis Sci. 1989;30:2285-92.
27. Simó-Servat O, Hernández C, Simó R. Genetics in diabetic retinopathy: current concepts and new insights. Curr Genomics. 2013;14:289-99.
28. Yoshii H, Uchino H, Ohmura C, Watanabe K, Tanaka Y, Kawamori R. Clinical usefulness of measuring urinary polyol excretion by gas-chromatography/mass spectrometry in type 2 diabetes to assess polyol pathway activity. Diabetes Res Clin Pract. 2001;51:115-23.
29. Chibber R, Molinatti PA, Kohner EM. Intracellular protein glycation in cultured retinal capillary pericytes and endothelial cells exposed to high-glucose concentration. Cell Mol Biol. 1999;45:47-57.
30. Stitt AW. The role of advanced glycation in the pathogenesis of diabetic retinopathy. Exp Mol Pathol. 2003;75:95-108.
31. Goldin A, Beckam JA, Schmidt AM, Creager MA. Advanced glycation en products: sparking the development of diabetic vascular injury. Circulation. 2006;114:597-605.
32. Schmidt AM, Yan SD, Wautier JL, Stern D. Activation of receptor for advanced glycation end products a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res. 1999;84:489-97.
33. Ways DK, Sheetz MJ. The role of protein kinase C in the development of the complications of diabetes. Vitam Horm. 2001;60:149-59.
34. Gurler B, Vural H, Yilmaz N, Oguz H, Satici A, Aksoy N. The role of oxidative stress in diabetic retinopathy. Eye. 2000;14:730-5.
35. Wirostko B, Wong TY, Simo R. Vascular endothelial growth factor and diabetic complications. Prog Reti Eye Res. 2008;27:608-21.
36. Miller J, Le Couter J, Strauss E, Ferrara N. Vascular endothelial growth factor A in intraocular vascular disease. Ophthalmology. 2012;120:106-14.
37. Boyer DS, Hopkins JJ, Sorof J, Ehrlich JS. Anti-vascular endothelial growth factor therapy for diabetic macular edema. Ther Adv Endocrinol Metab. 2013;4:151-69.
38. Stewart M. Anti-vascular endothelial growth factor drug treatment of diabetic macular edema: the evolution continues. Curr Diabetes Rev. 2012;8:237-46.
39. Iandiev I, Pannicke T, Reichel MB, Wiedemann P, Reichenbach A, Bringmann A. Expression of aquaporin-1 immunoreactivity by photoreceptor cells in the mouse retina. Neurosci Lett. 2005;388:96-9.
40. Uckermann O, Kutzera F, Wolf A, Panicke T, Reichenbach A, Wiedman P, et al. The glucocorticoid triamcinolone acetonide inhibits osmotic swelling of retinal glial cells via stimulation of endogenous adenosine signaling. J Pharmacol Exp Ther. 2005;315:1036-45.
41. Wilkinson CP, Ferris FL, Klein RE, Lee PP, Agardh CD, Davis M, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003;110:1677-82.
42. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991;98:766-85.
43. Ferris F. Early photocoagulation in patients with either type I or type II diabetes. Trans Am Ophthalmol Soc. 1996;94:505-37.
44. Mitchell P, Bandello F, Schmidt-Erfuth U, Lang GE, Masin P, Schlingeman RO, et al. The RESTORE study: ranibzumab mono therapy or combined with laser versus laser mono therapy for diabetic macular edma. Ophtalmology. 2011;118:615-25.
45. Stewart MW. Anti-VEGF therapy for diabetic macular edema. Curr Diab Rep. 2014;14:510.
46. Vaz F, Silva F, Henriques J. O que se entende por terapêutica combinada no tratamento da retinopatia diabética? In: Henriques J, Nascimento J, Silva F, coordenadores. 25 Perguntas e respostas: Retinopatia diabetic novo paradigma de cuidados. Lisboa: Grupo de Estudos da Retina; 2012.
47. Henriques J, Nascimento J, Rosa PC, Vaz FT, Amaro M. Laser fototérmico e sua interacção com a retina humana. Oftalmologia. 2012;36:353-64.
48. Rosa PC, Pinto R, Guitana M. Antiangiogénicos no tratamento da retinopatia diabética. In: Henriques J, Nascimento J, Silva F, coordenadores. 25 Perguntas e respostas: Retinopatia diabética novo paradigma de cuidados. Lisboa: Grupo de Estudos da Retina; 2012.
49. Cardillo JA, Melo LA Jr, Costa RA, Skaf M, Belfort R Jr, Souza-Filho AA, et al. Comparison of intravitreal versus posterior sub-Tenon’s capsule injection of triamcinolone acetonide for diffuse diabetic macular edema. Ophthalmology. 2005;112:1557-63.
50. Haller JA, Kuppermann BD, Blumenkranz MS, Williams GA, Weinberg DV, Chou C, et al. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol. 2010;128:289-96.
51. Shen X, Zhong Y, Xie B, Cheng Y, Jiao Q. Pigment epithelium derived factor as an anti-inflammatory factor against decrease of glutamine synthetase expression in retinal Müller cells under high glucose conditions. Graef Arch Clin Exp Ophthalmol. 2010;248:1127-36.
52. Tombran-Tink J, Barnstable CJ. Therapeutic prospects for PEDF: more than a promising angiogenesis inhibitor. Trends Mol Med. 2003;9:244-50.
53. Silva R. Perspetivas futuras no tratamento da retinopatia diabética. In: Henriques J, Nascimento J, Silva F, coordenadores. 25 Perguntas e respostas: Retinopatia diabética novo paradigma de cuidados. Lisboa: Grupo de Estudos da Retina; 2012.
54. Negi A, Vernon SA. An overview of the eye in diabetes. J R Soc Med. 2003;96:266-72.
55. Ino-ue M, Azumi A, Kajiura-Tsukahara Y, Yamamoto M. Ocular ischemic syndrome in diabetic patients. Jpn J Ophthalmol. 1999;43:31-35.
56. Lutty GA. Effects of diabetes on the eye. Invest Ophthalmol Vis Sci. 2013;54:ORSF 81-87.